[{"id":"24163a35-8b9c-475e-8999-ce9d118cb897","acronym":"SAKK 66/17","url":"https://clinicaltrials.gov/study/NCT03993678","created_at":"2021-01-18T19:38:09.158Z","updated_at":"2025-02-25T15:18:11.795Z","phase":"Phase 1/2","brief_title":"Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.","source_id_and_acronym":"NCT03993678 - SAKK 66/17","lead_sponsor":"Swiss Group for Clinical Cancer Research","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IP-001"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 10/12/2020","start_date":" 10/12/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-12"},{"id":"4d3e504a-d65c-4b69-ac5b-070f9d72f8ea","acronym":"SAKK 66/17","url":"https://clinicaltrials.gov/study/NCT03972436","created_at":"2021-01-18T19:32:29.201Z","updated_at":"2025-09-13T10:26:22.549Z","phase":"Phase 1/2","brief_title":"Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.","source_id_and_acronym":"NCT03972436 - SAKK 66/17","lead_sponsor":"Swiss Group for Clinical Cancer Research","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IP-001"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 08/01/2019","start_date":" 08/01/2019","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2019-06-03"}]